Advanced search×

Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model.

Shiro Higaki, Keizo Watanabe, Motoki Itahashi, and Yoshikazu Shimomura

Curr Eye Res 34(3):171-6 (2009) PMID 19274523

To examine the effects of COX inhibitors on suppressing HSV-1 reactivation in a mouse model.

DOI: 10.1080/02713680802650377
Version: za2963e q8zaf q8zb8 q8zca q8zd0 q8ze9 q8zf1 q8zg2
Buy PDF

Similar articles you may find interesting…

  1. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
    Prithviraj Bose, Gary L Simmons, and Steven Grant

    Expert Opin Investig Drugs (2013) PMID 23647051

    Cyclin-dependent kinases (CDKs) regulate cell cycle progression. Certain CDKs (e.g., CDK7, CDK9) also control cellular transcription. Consequently, CDKs represent attractive targets for anticancer drug development, as their aberrant expression is common in diverse malignancies, and CDK inhibition ca...
    Buy PDF
  2. Bortezomib down-modulates the survival factor IRF4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-...
    Marta Celegato, Cinzia Borghese, and Donatella Aldinucci

    Leuk Lymphoma (2013) PMID 23647062

    We investigated the effects of bortezomib activity in the presence of HL-associated fibroblasts (HL-AFs) and sCD40L. We found that co-cultivation with human HL-AFs or addition of sCD40L during bortezomib treatment protected cHL-cells from apoptosis and cytotoxicity and rescued the down-regulation of...
    Buy PDF
  3. surgical Treatment for Patients with Periodontal Disease Reduce End Stage Renal Disease Risk: A Nationwide Population-Based Retrospective Co...
    Chun-Feng Lee, Cheng-Li Lin, and Chia-Hung Kao

    J Periodontol (2013) PMID 23646848

    Patients with periodontal disease undergo operation for subgingival curettage and/or periodontal flap have a remarkably decreased risk of ESRD....
    Buy PDF